4olc › Citations

Structural basis for inactivation of Giardia lamblia carbamate kinase by disulfiram.

Galkin A, Kulakova L, Lim K, Chen CZ, Zheng W, Turko IV, Herzberg O
J Biol Chem 289 10502-10509 (2014)
Related entries: 3kzf, 4jz7, 4jz8, 4jz9

Cited: 36 times
EuropePMC logo PMID: 24558036

Abstract

Carbamate kinase from Giardia lamblia is an essential enzyme for the survival of the organism. The enzyme catalyzes the final step in the arginine dihydrolase pathway converting ADP and carbamoyl phosphate to ATP and carbamate. We previously reported that disulfiram, a drug used to treat chronic alcoholism, inhibits G. lamblia CK and kills G. lamblia trophozoites in vitro at submicromolar IC50 values. Here, we examine the structural basis for G. lamblia CK inhibition of disulfiram and its analog, thiram, their activities against both metronidazole-susceptible and metronidazole-resistant G. lamblia isolates, and their efficacy in a mouse model of giardiasis. The crystal structure of G. lamblia CK soaked with disulfiram revealed that the compound thiocarbamoylated Cys-242, a residue located at the edge of the active site. The modified Cys-242 prevents a conformational transition of a loop adjacent to the ADP/ATP binding site, which is required for the stacking of Tyr-245 side chain against the adenine moiety, an interaction seen in the structure of G. lamblia CK in complex with AMP-PNP. Mass spectrometry coupled with trypsin digestion confirmed the selective covalent thiocarbamoylation of Cys-242 in solution. The Giardia viability studies in the metronidazole-resistant strain and the G. lamblia CK irreversible inactivation mechanism show that the thiuram compounds can circumvent the resistance mechanism that renders metronidazole ineffectiveness in drug resistance cases of giardiasis. Together, the studies suggest that G. lamblia CK is an attractive drug target for development of novel antigiardial therapies and that disulfiram, an FDA-approved drug, is a promising candidate for drug repurposing.

Articles - 4olc mentioned but not cited (2)

  1. Structural basis for inactivation of Giardia lamblia carbamate kinase by disulfiram. Galkin A, Kulakova L, Lim K, Chen CZ, Zheng W, Turko IV, Herzberg O. J Biol Chem 289 10502-10509 (2014)
  2. The Repurposed Drug Disulfiram Inhibits Urease and Aldehyde Dehydrogenase and Prevents In Vitro Growth of the Oomycete Pythium insidiosum. Krajaejun T, Lohnoo T, Yingyong W, Rujirawat T, Kumsang Y, Jongkhajornpong P, Theerawatanasirikul S, Kittichotirat W, Reamtong O, Yolanda H. Antimicrob Agents Chemother 63 e00609-19 (2019)


Reviews citing this publication (9)

  1. Recent discovery and development of inhibitors targeting coronaviruses. Pillaiyar T, Meenakshisundaram S, Manickam M. Drug Discov Today 25 668-688 (2020)
  2. Treatment-refractory giardiasis: challenges and solutions. Lalle M, Hanevik K. Infect Drug Resist 11 1921-1933 (2018)
  3. Development of Small-Molecule MERS-CoV Inhibitors. Liang R, Wang L, Zhang N, Deng X, Su M, Su Y, Hu L, He C, Ying T, Jiang S, Yu F. Viruses 10 E721 (2018)
  4. Sources and Fates of Carbamyl Phosphate: A Labile Energy-Rich Molecule with Multiple Facets. Shi D, Caldovic L, Tuchman M. Biology (Basel) 7 E34 (2018)
  5. Giardia duodenalis Virulence - "To Be, or Not To Be". Argüello-García R, Ortega-Pierres MG. Curr Trop Med Rep 8 246-256 (2021)
  6. Therapeutic approaches against coronaviruses acute respiratory syndrome. Servidio C, Stellacci F. Pharmacol Res Perspect 9 e00691 (2021)
  7. Parasitic diarrheal disease: drug development and targets. Azam A, Peerzada MN, Ahmad K. Front Microbiol 6 1183 (2015)
  8. Disulfiram: Mechanisms, Applications, and Challenges. Lanz J, Biniaz-Harris N, Kuvaldina M, Jain S, Lewis K, Fallon BA. Antibiotics (Basel) 12 524 (2023)
  9. The Use of Natural Bioactive Nutraceuticals in the Management of Tick-Borne Illnesses. Shor SM, Schweig SK. Microorganisms 11 1759 (2023)

Articles citing this publication (25)

  1. Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes. Lin MH, Moses DC, Hsieh CH, Cheng SC, Chen YH, Sun CY, Chou CY. Antiviral Res 150 155-163 (2018)
  2. Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors. Ma C, Hu Y, Townsend JA, Lagarias PI, Marty MT, Kolocouris A, Wang J. ACS Pharmacol Transl Sci 3 1265-1277 (2020)
  3. FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication. Lobo-Galo N, Terrazas-López M, Martínez-Martínez A, Díaz-Sánchez ÁG. J Biomol Struct Dyn 39 3419-3427 (2021)
  4. Disulfiram and Copper Ions Kill Mycobacterium tuberculosis in a Synergistic Manner. Dalecki AG, Haeili M, Shah S, Speer A, Niederweis M, Kutsch O, Wolschendorf F. Antimicrob Agents Chemother 59 4835-4844 (2015)
  5. Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays. Ma C, Tan H, Choza J, Wang Y, Wang J. Acta Pharm Sin B 12 1636-1651 (2022)
  6. Glutathione, glutathione disulfide, and S-glutathionylated proteins in cell cultures. Giustarini D, Galvagni F, Tesei A, Farolfi A, Zanoni M, Pignatta S, Milzani A, Marone IM, Dalle-Donne I, Nassini R, Rossi R. Free Radic Biol Med 89 972-981 (2015)
  7. Discovery of novel antigiardiasis drug candidates. Kulakova L, Galkin A, Chen CZ, Southall N, Marugan JJ, Zheng W, Herzberg O. Antimicrob Agents Chemother 58 7303-7311 (2014)
  8. Disulfiram (Tetraethylthiuram Disulfide) in the Treatment of Lyme Disease and Babesiosis: Report of Experience in Three Cases. Liegner KB. Antibiotics (Basel) 8 E72 (2019)
  9. Drug Repurposing of the Alcohol Abuse Medication Disulfiram as an Anti-Parasitic Agent. Shirley DA, Sharma I, Warren CA, Moonah S. Front Cell Infect Microbiol 11 633194 (2021)
  10. COVID-19 therapy: What weapons do we bring into battle? de Almeida SMV, Santos Soares JC, Dos Santos KL, Alves JEF, Ribeiro AG, Jacob ÍTT, da Silva Ferreira CJ, Dos Santos JC, de Oliveira JF, de Carvalho Junior LB, de Lima MDCA. Bioorg Med Chem 28 115757 (2020)
  11. Inhibitors of methionyl-tRNA synthetase have potent activity against Giardia intestinalis trophozoites. Ranade RM, Zhang Z, Gillespie JR, Shibata S, Verlinde CL, Hol WG, Fan E, Buckner FS. Antimicrob Agents Chemother 59 7128-7131 (2015)
  12. Disulfiram as a novel inactivator of Giardia lamblia triosephosphate isomerase with antigiardial potential. Castillo-Villanueva A, Rufino-González Y, Méndez ST, Torres-Arroyo A, Ponce-Macotela M, Martínez-Gordillo MN, Reyes-Vivas H, Oria-Hernández J. Int J Parasitol Drugs Drug Resist 7 425-432 (2017)
  13. Proteomic and functional analyses reveal pleiotropic action of the anti-tumoral compound NBDHEX in Giardia duodenalis. Camerini S, Bocedi A, Cecchetti S, Casella M, Carbo M, Morea V, Pozio E, Ricci G, Lalle M. Int J Parasitol Drugs Drug Resist 7 147-158 (2017)
  14. Repurposing Disulfiram (Tetraethylthiuram Disulfide) as a Potential Drug Candidate against Borrelia burgdorferi In Vitro and In Vivo. Potula HSK, Shahryari J, Inayathullah M, Malkovskiy AV, Kim KM, Rajadas J. Antibiotics (Basel) 9 E633 (2020)
  15. Inhibition of Urease by Disulfiram, an FDA-Approved Thiol Reagent Used in Humans. Díaz-Sánchez ÁG, Alvarez-Parrilla E, Martínez-Martínez A, Aguirre-Reyes L, Orozpe-Olvera JA, Ramos-Soto MA, Núñez-Gastélum JA, Alvarado-Tenorio B, de la Rosa LA. Molecules 21 E1628 (2016)
  16. Identification and Validation of Small-Gatekeeper Kinases as Drug Targets in Giardia lamblia. Hennessey KM, Smith TR, Xu JW, Alas GC, Ojo KK, Merritt EA, Paredez AR. PLoS Negl Trop Dis 10 e0005107 (2016)
  17. High-Throughput Fluorescent Assay for Inhibitor Screening of Proteases from RNA Viruses. Cihlova B, Huskova A, Böserle J, Nencka R, Boura E, Silhan J. Molecules 26 3792 (2021)
  18. Disulfiram: A Repurposed Drug in Preclinical and Clinical Development for the Treatment of Infectious Diseases. Custodio MM, Sparks J, Long TE. Antiinfect Agents 20 e040122199856 (2022)
  19. Click chemistry-facilitated comprehensive identification of proteins adducted by antimicrobial 5-nitroimidazoles for discovery of alternative drug targets against giardiasis. Lauwaet T, Miyamoto Y, Ihara S, Le C, Kalisiak J, Korthals KA, Ghassemian M, Smith DK, Sharpless KB, Fokin VV, Eckmann L. PLoS Negl Trop Dis 14 e0008224 (2020)
  20. Discovery and Preclinical Development of Antigiardiasis Fumagillol Derivatives. Padia J, Kulakova L, Galkin A, Herzberg O. Antimicrob Agents Chemother 64 e00582-20 (2020)
  21. Establishment of Canine-Derived Giardia duodenalis Isolates in Culture. Tysnes KR, Robertson LJ. J Parasitol 102 342-348 (2016)
  22. Disulfiram blocked cell entry of SARS-CoV-2 via inhibiting the interaction of spike protein and ACE2. Chen HF, Hsueh PR, Liu YY, Chen Y, Chang SY, Wang WJ, Wu CS, Tsai YM, Liu YS, Su WC, Chou YC, Hung MC. Am J Cancer Res 12 3333-3346 (2022)
  23. Antigiardial Activity of Novel Guanidine Compounds. Stevens AJ, Abraham R, Young KA, Russell CC, McCluskey SN, Baker JR, Rusdi B, Page SW, O'Handley R, O'Dea M, Abraham S, McCluskey A. ChemMedChem 17 e202200341 (2022)
  24. Hyperthermophilic Carbamate Kinase Stability and Anabolic In Vitro Activity at Alkaline pH. Hennessy JE, Latter MJ, Fazelinejad S, Philbrook A, Bartkus DM, Kim HK, Onagi H, Oakeshott JG, Scott C, Alissandratos A, Easton CJ. Appl Environ Microbiol 84 e02250-17 (2018)
  25. Reactivity and binding mode of disulfiram, its metabolites, and derivatives in SARS-CoV-2 PLpro: insights from computational chemistry studies. Nogara PA, Omage FB, Bolzan GR, Delgado CP, Orian L, Rocha JBT. J Mol Model 28 354 (2022)


Related citations provided by authors (2)

  1. X-ray structure and characterization of carbamate kinase from the human parasite Giardia lamblia.. Galkin A, Kulakova L, Wu R, Nash TE, Dunaway-Mariano D, Herzberg O Acta Crystallogr Sect F Struct Biol Cryst Commun 66 386-90 (2010)
  2. Crystal structures of carbamate kinase from Giardia lamblia bound with citric acid and AMP-PNP.. Lim K, Kulakova L, Galkin A, Herzberg O PLoS One 8 e64004 (2013)

Quick links